Nice — here’s a compact, source-backed market reference for the Nasal / Intranasal Drug Delivery Market with the sections you asked for and a short list of major companies with the kinds of values/metrics market reports actually publish (market share, role, transaction values, product/installed-base notes). I used recent market reports, reviews and news items; the most important factual claims are cited so you can follow up.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Nasal Drug Delivery market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Nasal Drug Delivery market.

Read complete report at: https://www.thebrainyinsights.com/report/nasal-drug-delivery-market-13890

Quick note on scope: different publishers define the market differently (some include vaccines, sprays, dry-powder systems, devices + biologics). I therefore cite multiple reputable estimates so you can pick the scope you prefer.

Quick load-bearing facts

• Market size (examples): Databridge estimates ~USD 69.9 billion in 2024 (to USD 119.3B by 2032, CAGR ~6.9%). Grand View / GMI / other sources report USD ~72–77B (2023/2024) with mid-single-digit CAGRs (~6–7%). Precedence / device-only reports place the intranasal device market much smaller (~USD 1.7–1.9B in 2024) because they exclude drug revenues. 

Recent developments

• Public funding & vaccine focus: U.S. HHS/BARDA committed funding programs to support oral/nasal COVID vaccine trials (e.g., Project NextGen), boosting R&D investment in intranasal vaccines and platform technologies. 

• Industry M&A / supply-chain moves: device suppliers and pharma partners are making strategic moves (examples: Aptar’s acquisitions and expanded nasal capabilities; device OEMs investing in dedicated nasal manufacturing). Reports cite deal activity and facility investments in 2023–2025. 

• Litigation & component-supply tensions: high-profile legal disputes over device components (e.g., ARS vs Aptar antitrust litigation concerning nasal spray components) have surfaced, highlighting supply-chain concentration risks for single-use/critical devices. 

Drivers

• Rapid onset & non-invasive delivery (avoids first-pass metabolism; useful for analgesics, rescue meds, CNS / nose-to-brain programs). 

• Vaccine & biologic interest (mucosal immunity goals for respiratory pathogens; airway/olfactory routes for nose-to-brain delivery). 

• Patient preference & point-of-care use (needle-free emergency products, home administration, pediatric applications such as FluMist expansion). 

Restraints

• Biological & formulation barriers (mucociliary clearance, enzymatic degradation, limited volume and absorption window) — technical hurdles for large molecules and consistent bioavailability. 

• Supply-chain concentration & component risk (few suppliers of specialized components can cause delays / price pressure). Recent litigation in the sector underscores this risk. 

Regional segmentation (high level)

• North America: largest current market share (reports often place NA ~30–40% of total value) and strongest investment in R&D / vaccines. 

• Asia-Pacific: fastest growing region in most forecasts (large patient pools, rising vaccine/dev programs and growing pharma manufacturing). 

• Europe / LatAm / MEA: important markets for allergy / rhinitis products and growing for vaccines and biologics depending on local uptake. 

Emerging trends

• Nose-to-brain therapies & CNS targeting — increasing academic and industry work on delivering neurotherapeutics via the olfactory/trigeminal pathways. 

• Polymer/device innovation (single-use emergency sprays, multidose preservative-free systems, DPIs for nasal use) and dedicated nasal platforms (OEMs scaling capacity). 

• Connected nasal devices & patient adherence programs (less mature than other DME categories but growing in interest). 

Top use-cases

1. Allergic rhinitis / nasal sprays (largest volume products). 

2. Respiratory vaccines and prophylactics (intranasal flu, COVID candidates). 

3. Emergency rescue therapies (e.g., intranasal naloxone, intranasal epinephrine).

4. Neurological (nose-to-brain) therapeutics and analgesics. 

Major challenges

• Translating preclinical nose-to-brain promise to reliable clinical outcomes (bioavailability, device/formulation pairing). 

• Regulatory complexity for intranasal biologics & vaccines (bridging immunogenicity, mucosal endpoints).

• Market fragmentation in device supply (OEMs vs pharma proprietary systems; component shortages can bottleneck launches).

Attractive opportunities

• Intranasal vaccines & prophylactics (mucosal immunity — big addressable market if efficacy proven). BARDA/public funding makes this a near-term priority. 

• Needle-free emergency treatments (epinephrine, naloxone) — high convenience & patient adoption potential.

• Platform/device partnerships — pharma + device OEM collaborations (contract device manufacturers scaling nasal solutions) to speed combinations to market. 

Key factors of market expansion

• Clinical success of intranasal vaccines / biologics (demonstrated mucosal efficacy would be catalytic).

• Regulatory clarity & reimbursement pathways for outpatient / home administration.

• Scale in OEM manufacturing capacity and component diversification to reduce supply-chain bottlenecks. Recent investments and factory builds by device OEMs are signs of this scaling.

Major companies — what reports actually report (role / value / metric)

Market reports usually publish company role (leader / OEM / pharma adopter), product references, property counts, transaction values and occasionally market-share slices — they rarely publish a clean “nasal-only revenue” line for diversified companies. below are the firms most commonly named and the type of value/metric you’ll find reported about them:

• Aptar Pharma (AptarGroup) — Device OEM & leader in nasal spray systems; public filings show company-level sales and Aptar often cited for strategic acquisitions / facility investments in nasal devices (Aptar reported FY-2024 results in investor releases). Example metrics reported in industry press: product wins, acquisition activity and company sales results.

• Nemera — Leading drug-delivery OEM (multi-dose pumps, single-dose Unispray, dedicated nasal platforms); cited for high manufacturing volumes and market references. Reports cite Nemera’s production scale (millions of units annually) and product examples.

• GlaxoSmithKline (GSK) — Pharma adopter & vaccine manufacturer (FluMist historically; major presence in nasal vaccine products and formulations). Market/news items cite product approvals and distribution initiatives. 

• AstraZeneca — Developer/marketer of intranasal vaccines (e.g., flu products via partners) and large pharma involvement in respiratory intranasal programs.

• Pfizer / Merck / Johnson & Johnson (J&J) — Large pharma names frequently listed in market vendor rosters (they appear in reports as developers or users of nasal routes for certain programs or device partnerships).

• Contract manufacturing / specialty OEMs & component suppliers: Silgan Dispensing, West Pharmaceutical, Gerresheimer, Catalent — often cited for components, fill/finish or device outsourcing. Reports highlight their role in supply capacity and component availability rather than a “nasal revenue” line.

• Small / biotech developers & platform companies: Vaxart, Altimmune, Castlevax, Cyanvac, ARS Pharmaceuticals — appear in news as developers of oral/nasal vaccine or therapeutic candidates; some receive government funding or approvals for specific products (e.g., ARS’s epinephrine product approvals and the related device supply litigation). 

Example concrete values / transactional items reported in the literature

• Market totals: Databridge ≈ USD 69.9B (2024); Grand View / GMI / MDPI show similar USD 70–77B class totals for combined drug+device markets (device-only estimates are in the ~USD 1.7–1.9B range).

• Public funding: U.S. HHS/BARDA announced funding (Project NextGen) that included up to $500M for oral/nasal vaccine studies (announced Jun 2024). That funding materially changes risk capital availability for intranasal vaccine programs.

• OEM investment / deals: industry reports and press cite acquisitions and facility investments by Aptar and other device OEMs (e.g., Aptar’s acquisition activity and product investments).

Want a table with numeric company values?

I can compile any of the following right now (I’ll extract numbers & cite sources):

1. Top 20 companies — columned with: (a) company role (OEM / pharma / CM), (b) cited metric (market share / transaction / facility investment / product example), and (c) source citation.

2. Company financials — FY2023/2024 revenue for a selected vendor list (Aptar, Nemera (if available), GSK, AstraZeneca, Pfizer, Vaxart) and any publicly-reported nasal-segment numbers or deal values.

3. Region-by-region 2024 market size + CAGR (NA / EU / APAC / LATAM / MEA) as a CSV.

Pick which table you want and I’ll extract the numbers and return a neatly sourced table.